四项随机临床试验个体水平分析:降压对肾脏分层复合结局的赢家统计评估
该事后分析纳入SPRINT、ACCORD-BP、SHEP和ALLHAT四项试验共61248例参与者,采用七层复合肾脏终点(HCE)和赢家比值(WO)评估强化降压及不同药物对肾脏结局的影响。结果显示强化降压在SPRINT和ACCORD-BP中WO不利,SHEP中氯噻酮劣于安慰剂,ALLHAT中多沙唑嗪和氨氯地平优于氯噻酮,eGFR斜率组分贡献超过50%。
要点
- 强化降压在SPRINT和ACCORD-BP中肾脏复合结局的WO均不利。
- SHEP中氯噻酮肾脏结局劣于安慰剂,ALLHAT中多沙唑嗪和氨氯地平优于氯噻酮。
- eGFR斜率是赢家统计的主要驱动因素,贡献超过50%。
核心结论
- 强化降压和氯噻酮与较不利的中期eGFR轨迹相关,主要驱动因素为eGFR斜率。
- 结果支持监测肾功能以优化心血管保护与肾脏保护之间的平衡。
研究设计与样本
- 四项大型随机临床试验(SPRINT、ACCORD-BP、SHEP、ALLHAT)的个体水平数据事后分析。
- 共纳入61248例参与者,各试验中位随访时间为46至60个月。
- 采用七层复合肾脏终点(HCE),按临床严重程度排序:全因死亡、肾衰竭、eGFR低于15 mL/min/1.73m2、eGFR下降57%/50%/40%或以上、三年总eGFR斜率。
- 缺失结局按结处理,计算赢家比值(WO)。
主要发现
- SPRINT中强化降压相比标准治疗WO为0.61(95%CI 0.58-0.64)。
- ACCORD-BP中强化降压相比标准治疗WO为0.64(95%CI 0.59-0.68)。
- SHEP中氯噻酮相比安慰剂WO为0.89(95%CI 0.84-0.95)。
- ALLHAT中多沙唑嗪相比氯噻酮WO为1.29(95%CI 1.25-1.33),氨氯地平相比氯噻酮WO为1.38(95%CI 1.34-1.42),赖诺普利相比氯噻酮WO为0.96(95%CI 0.93-0.98)。
- eGFR斜率组分在各试验中对赢家统计的贡献超过50%,亚组和敏感性分析结果 broadly 一致。
临床怎么用
- 临床中应监测肾功能,以平衡强化降压的心血管获益与肾脏保护。
- 选择降压药物时需考虑不同药物对肾脏结局的潜在差异。
局限性
- 为事后分析,结果需谨慎解读。
- 缺失结局按结处理可能影响估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite established cardiovascular benefits, the effects of intensive blood pressure (BP) lowering and specific agents on kidney function remain debated. Here, we assessed these effects using a validated hierarchical composite kidney endpoint (HCE) that prioritizes clinical severity. METHODS: This post hoc analysis used individual-level data from four large randomized clinical trials: SPRINT, ACCORD-BP, SHEP, and ALLHAT. The seven-tier HCE ranked components by clinical severity: all-cause mortality, kidney failure, estimated glomerular filtration rate (eGFR) under 15 mL/min/1.73m2, eGFR declines of 57%/50%/40% or more, and three-year total eGFR slope. We estimated Win Odds (WO) for all randomized participants, with missing outcomes handled as ties. RESULTS: A total of 61,248 participants were included with median follow-ups of 46 to 60 months across trials. Intensive BP treatment yielded unfavorable WO compared with standard treatment in SPRINT (WO, 0.61 [95% confidence interval, 0.58-0.64]) and ACCORD-BP (WO, 0.64 [0.59-0.68]. In SHEP, chlorthalidone was inferior to placebo (WO, 0.89 [0.84-0.95]). In ALLHAT, doxazosin (WO, 1.29 [1.25-1.33]) and amlodipine (WO, 1.38 [1.34-1.42]) outperformed chlorthalidone, while lisinopril was slightly less favorable (WO, 0.96 [0.93-0.98]). The eGFR slope component contributed over 50% to the win statistics across trials. Results were broadly consistent across subgroups and sensitivity analyses. CONCLUSIONS: Our hierarchical analysis indicated that intensive BP lowering and chlorthalidone were associated with less favorable mid-term eGFR trajectories. Driven largely by the eGFR slope, which represents a sensitive signal of kidney reserve depletion, our findings support monitoring kidney function to optimize the balance between cardiovascular protection and kidney preservation. TRIAL REGISTRATION: Registered at Clinicaltrials.gov with study numbers NCT01206062, NCT00000620, NCT00000514, and NCT00000542.
引用
- Liu Y, Lyu Y, Liu Y, et al. Individual participant-level analysis of four randomized clinical trials examined therapeutic effects of blood pressure lowering on hierarchical kidney outcome using win statistics. Kidney Int. 2026. PMID: 41903707. doi:10.1016/j.kint.2026.02.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。